SCHEMBL3603923

SCHEMBL3603923

NC(=O)c1c(-c2ccccc2)[nH]c(-c2nc(N)ncc2Br)c1I

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 8/20 0.65
IKBKB O14920 1/20 0.41
CCNT1 O60563 1/20 0.41
JAK2 O60674 1/20 0.41
CCNB2 O95067 1/20 0.41
CCNE2 O96020 1/20 0.41
PRKCB P05771 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3B P49841 1/20 0.41
CDK9 P50750 1/20 0.41
CCNA1 P78396 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
ADORA1 P30542 6/20 0.39
ADORA2A P29274 4/20 0.39
CLK1 P49759 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183402 0.89 CDC7 (0.66) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL4187750 0.88 CDC7 (0.65) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL3596692 0.84 CDC7 (0.52) CDC7KMT2A
SCHEMBL27738533 0.84 CDC7 (0.62) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL4182044 0.79 CDC7 (1.00) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL28775682 0.78 CDC7 (0.64) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL4190784 0.77 CDC7 (1.00) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL28779560 0.75 CDC7 (0.80) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL13977106 0.74 CDC7 (0.62) CDC7IKBKBCCNT1JAK2CCNB2
SCHEMBL15300434 0.74 CDC7 (0.71) CDC7IKBKBCCNT1JAK2CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 US disclosed
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) 2025-09-04 US disclosed
EP-4247790-B1 STING ANTAGONISTS AND USES THEREOF REGOR PHARMACEUTICALS INC (US) 2024-10-09 EP disclosed
WO-2024148210-A1 CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2024-07-11 WO disclosed
US-20240051956-A1 SOS1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2024-02-15 US disclosed
US-20240002368-A1 STING ANTAGONISTS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2024-01-04 US disclosed
EP-4267250-A1 SOS1 INHIBITORS AND USES THEREOF Qilu Regor Therapeutics Inc. (CN) 2023-11-01 EP disclosed
WO-2023195530-A1 URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 塩野義製薬株式会社 2023-10-12 WO disclosed
WO-2023195529-A1 URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 塩野義製薬株式会社 2023-10-12 WO disclosed
WO-2022140427-A1 SOS1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-06-30 WO disclosed
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-04-16 US disclosed
EP-2004623-A1 PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2008-12-24 EP disclosed
WO-2008065054-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-05 WO disclosed
EP-1756086-B1 PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
WO-2007110344-A1 PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-10-04 WO disclosed
EP-1756086-A1 PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
US-7183435-B2 Hexasubstituted with a tertiary amino phenyl groups; stability, rapid response and good transportability; electrophotographic photoreceptor RICOH COMPANY, LTD. (JP) 2007-02-27 US disclosed
US-20060030559-A1 Diazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 US disclosed
US-20060024595-A1 Triphenylene compound, method for making RICOH COMPANY, LTD. (JP) 2006-02-02 US disclosed
WO-2005118568-A1 PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060024595-A1 Triphenylene compound, method for making ALDH1A2, PDE6C, NR2E3 CDC7 2884/4885IKBKB 4306/4885CCNT1 1858/4885
US-20090099221-A1 PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS CDK2, CDK1, CDK5 CDC7 294/4885IKBKB 684/4885CCNT1 84/4885
US-20060030559-A1 Diazole derivatives GRM1, GRM2, GRIN2B CDC7 4692/4885IKBKB 3956/4885CCNT1 1773/4885
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF CRBN, PSMB3, PSMB1 CDC7 872/4885IKBKB 1144/4885CCNT1 452/4885
US-20240002368-A1 STING ANTAGONISTS AND USES THEREOF STING1, TBK1, CGAS CDC7 2403/4885IKBKB 105/4885CCNT1 4869/4885
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS PACSIN2, CSNK1A1, CSNK1G3 CDC7 229/4885IKBKB 246/4885CCNT1 705/4885
US-20240051956-A1 SOS1 INHIBITORS AND USES THEREOF SOS1, KRAS, NRAS CDC7 1754/4885IKBKB 497/4885CCNT1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.